LogicBio Therapeutics (LOGC) Misses Q2 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
Financial Fact:
Research and development: 124.3K
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 124.3K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.50).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Envista Holdings Corp. (NVST) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY26 Guidance
- Miller Industries (MLR) Misses Q3 EPS by 11c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
